[Federal Register Volume 67, Number 177 (Thursday, September 12, 2002)]
[Notices]
[Pages 57853-57854]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-23112]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to The National Cooperative Research and 
Production Act of 1993--Technologies for Target Assessment

    Notice is hereby given that, on August 1, 2002, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Technologies for Target 
Assessment has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identities of the parties and (2) the nature and objectives of the 
venture. The notifications were filed for the purpose of invoking the 
Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances. Pursuant to Section 6(b) 
of the Act, the identities of the parties are Paradigm Genetics, Inc., 
Research Triangle Park, NC; and LION Bioscience, Cleveland, OH. The 
nature and objectives of the venture are to assemble and develop a 
software suite and data solution that allows users to better identify 
targets of lead compound discovery and product development by 
integrating large streams of biological and biochemical data from 
heterogeneous sources into coherent data sets that accurately represent 
underlying biological relationships. If successful, the project will 
lead to a

[[Page 57854]]

Target Assessment Technologies Suite (TATS) of software and database 
products applicable to any organism or cell culture system. TATS goes 
beyond data integration to allow researchers to create, validate and 
analyze coherent data sets to identify high quality targets. The 
ability to compare data across multiple research platforms in a way 
that is biologically relevant and statistically sound will greatly 
improve the ability to identify gene function and increase the number 
of product leads that succeed in clinical trials in the pharmaceutical 
and agrochemical industries.

Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 02-23112 Filed 9-11-02; 8:45 am]
BILLING CODE 4410-11-M